Literature DB >> 31190121

Bone mass density and bone metabolism marker are associated with progression of carotid and cardiac calcified plaque in Chinese elderly population.

D Liu1, L Chen2, S Dong2, Z Peng3, H Yang3, Y Chen3, L Li3, H Zhou3, R Zhou4.   

Abstract

Osteoporosis and cardiovascular diseases often coexist in the same elderly individuals. Does this suggest some potential correlation between the two diseases? Low bone mass and change of bone biomarker are associated with a higher risk of carotid and cardiac calcification plaques.
INTRODUCTION: Bone mineral density (BMD) and bone metabolism marker may contribute to the progression of carotid and cardiac arterial calcifications. The aim of this study was to investigate whether low bone mass and the change of bone biomarker are associated with the prevalence of calcified atherosclerotic plaque in elderly Chinese.
METHODS: We conducted a five-year prospective study. BMD was measured by dual-energy X-ray absorptiometry scanning. Carotid and cardiac computed tomography angiography (CTA) was conducted using a 64-multidetector row scanner to assess carotid and cardiac arterial plaque at baseline and during follow-up.
RESULTS: Of 1571 community residents over 60 years of age, 184 (11.7%) subjects developed carotid calcified plaque, 510 (32.5%) subjects developed cardiac calcified plaque and 97 (6.2%) subjects developed co-existence calcified plaques in carotid and cardiac arteries. After adjustment for age and all relevant confounders, Q1, Q2 quartile of BMD, and osteoprotegerin (OPG), osteocalcin (OC), and C-terminal cross-linked telopeptide of type I collagen (CTX) were associated with increased risk of calcified plaques.
CONCLUSION: This study suggested that lower BMD and change of bone metabolism biomarker were associated with a higher risk of carotid and cardiac calcified plaque development.

Entities:  

Keywords:  Bone metabolism marker; Bone mineral density; Calcified plaque; Cardiac artery; Carotid artery

Mesh:

Substances:

Year:  2019        PMID: 31190121     DOI: 10.1007/s00198-019-05031-5

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  38 in total

1.  Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans.

Authors:  Anders Vik; Ellisiv B Mathiesen; Ann-Trude W Notø; Baldur Sveinbjørnsson; Jan Brox; John-Bjarne Hansen
Journal:  Atherosclerosis       Date:  2006-04-18       Impact factor: 5.162

2.  Aortic valve calcification: association with bone mineral density and cardiovascular risk factors.

Authors:  Yuksel Aksoy; Cengiz Yagmur; Gulacan Ozgun Tekin; Julide Yagmur; Ergun Topal; Ersoy Kekilli; Hasan Turhan; Feridun Kosar; Ertan Yetkin
Journal:  Coron Artery Dis       Date:  2005-09       Impact factor: 1.439

3.  Vitamin D deficiency.

Authors:  Roger Bouillon; Anthony W Norman; Paul Lips
Journal:  N Engl J Med       Date:  2007-11-08       Impact factor: 91.245

4.  Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease.

Authors:  Stefan Kiechl; Georg Schett; Gregor Wenning; Kurt Redlich; Martin Oberhollenzer; Agnes Mayr; Peter Santer; Josef Smolen; Werner Poewe; Johann Willeit
Journal:  Circulation       Date:  2004-04-26       Impact factor: 29.690

5.  Low bone mineral density is related to echogenic carotid artery plaques: a population-based study.

Authors:  Lone Jørgensen; Oddmund Joakimsen; Gro K Rosvold Berntsen; Ivar Heuch; Bjarne K Jacobsen
Journal:  Am J Epidemiol       Date:  2004-09-15       Impact factor: 4.897

6.  Calcified atherosclerotic plaque and bone mineral density in type 2 diabetes: the diabetes heart study.

Authors:  J Jeffrey Carr; Thomas C Register; Fang-Chi Hsu; Kurt Lohman; Leon Lenchik; Donald W Bowden; Carl D Langefeld; Jianzhou Xu; Stephen S Rich; Lynne E Wagenknecht; Barry I Freedman
Journal:  Bone       Date:  2007-08-22       Impact factor: 4.398

Review 7.  Diagnosis of osteoporosis and assessment of fracture risk.

Authors:  John A Kanis
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

8.  Low bone mass is associated with carotid atherosclerosis in postmenopausal women: the Japanese Population-based Osteoporosis (JPOS) Cohort Study.

Authors:  J Tamaki; M Iki; Y Hirano; Y Sato; E Kajita; S Kagamimori; Y Kagawa; H Yoneshima
Journal:  Osteoporos Int       Date:  2008-05-22       Impact factor: 4.507

9.  Carotid atherosclerosis is a stronger predictor of myocardial infarction in women than in men: a 6-year follow-up study of 6226 persons: the Tromsø Study.

Authors:  Stein Harald Johnsen; Ellisiv B Mathiesen; Oddmund Joakimsen; Eva Stensland; Tom Wilsgaard; Maja-Lisa Løchen; Inger Njølstad; Egil Arnesen
Journal:  Stroke       Date:  2007-09-27       Impact factor: 7.914

10.  Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction.

Authors:  Thor Ueland; Rune Jemtland; Kristin Godang; John Kjekshus; Aina Hognestad; Torbjørn Omland; Iain B Squire; Lars Gullestad; Jens Bollerslev; Kenneth Dickstein; Pål Aukrust
Journal:  J Am Coll Cardiol       Date:  2004-11-16       Impact factor: 24.094

View more
  3 in total

1.  Fasudil Ameliorates Osteoporosis Following Myocardial Infarction by Regulating Cardiac Calcitonin Secretion.

Authors:  Chengyu Xiang; Yeqian Zhu; Maohua Xu; Dingguo Zhang
Journal:  J Cardiovasc Transl Res       Date:  2022-05-12       Impact factor: 4.132

2.  Association between total type I collagen N-terminal propeptide and coronary artery disease risk score in the general Japanese population.

Authors:  Hiroto Kikuchi; Takahito Nasu; Mamoru Satoh; Yuka Kotozaki; Kozo Tanno; Koichi Asahi; Hideki Ohmomo; Takamasa Kobayashi; Satoru Taguchi; Yoshihiro Morino; Atsushi Shimizu; Kenji Sobue; Makoto Sasaki
Journal:  Int J Cardiol Heart Vasc       Date:  2022-05-19

Review 3.  Serum biomarkers for arterial calcification in humans: A systematic review.

Authors:  Nienke M S Golüke; Marit A Schoffelmeer; Annemarieke De Jonghe; Mariëlle H Emmelot-Vonk; Pim A De Jong; Huiberdina L Koek
Journal:  Bone Rep       Date:  2022-06-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.